ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
11 hedge funds and large institutions have $2.52M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
9% less capital inflows, than outflows
Capital inflows: $1.19M | Capital outflows: $1.31M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$753K |
| 2 |
Jane Street
New York
|
+$350K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$77.1K |
| 4 |
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
|
+$9.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$1.07M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$220K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$17K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$548 |
CNCR Hedge Fund Activity: Q2 2016 in Review
11 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q2 2016, worth a combined $2.52M — down 2.6% from $2.58M a quarter earlier.
Fund positioning in CNCR was balanced in Q2 2016: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $753K. The largest seller was LPL Financial, cutting an estimated $1.07M.
- 11 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $2.52M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q2 2016, down 2.6% quarter-over-quarter.
- 2 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q2 2016 and 2 closed out, a net change of 0 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q2 2016 was Susquehanna International Group, an estimated $753K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q2 2016 was LPL Financial, an estimated $1.07M sold.
Based on aggregated 13F filings for Q2 2016.